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Objective: The first aim of this study was to develop a nanocarrier that could transport the 
peroxisome proliferator-activated receptor agonist, pioglitazone (PGZ) across brain endothelium 
and examine the mechanism of nanoparticle transcytosis. The second aim was to determine 
whether these nanocarriers could successfully treat a mouse model of Alzheimer’s disease (AD).
Methods: PGZ-loaded nanoparticles (PGZ-NPs) were synthesized by the solvent displacement 
technique, following a factorial design using poly (lactic-co-glycolic acid) polyethylene glycol 
(PLGA-PEG). The transport of the carriers was assessed in vitro, using a human brain endothelial 
cell line, cytotoxicity assays, fluorescence-tagged nanocarriers, fluorescence-activated cell sorting, 
confocal and transmission electron microscopy. The effectiveness of the treatment was assessed 
in APP/PS1 mice in a behavioral assay and by measuring the cortical deposition of β-amyloid.
Results: Incorporation of PGZ into the carriers promoted a 50x greater uptake into brain 
endothelium compared with the free drug and the carriers showed a delayed release profile of 
PGZ in vitro. In the doses used, the nanocarriers were not toxic for the endothelial cells, nor 
did they alter the permeability of the blood–brain barrier model. Electron microscopy indicated 
that the nanocarriers were transported from the apical to the basal surface of the endothelium 
by vesicular transcytosis. An efficacy test carried out in APP/PS1 transgenic mice showed a 
reduction of memory deficit in mice chronically treated with PGZ-NPs. Deposition of β-amyloid 
in the cerebral cortex, measured by immunohistochemistry and image analysis, was correspond-
ingly reduced.
Conclusion: PLGA-PEG nanocarriers cross brain endothelium by transcytosis and can be 
loaded with a pharmaceutical agent to effectively treat a mouse model of AD.
Keywords: nanoparticle, Alzheimer’s disease, blood–brain barrier, brain endothelium, pioglitazone, 
APP/PS1 transgenic mouse
Introduction
Alzheimer’s disease (AD) is a multifactorial brain disorder prevalent in elderly 
people.1,2 It is characterized by cognitive impairment, synaptic failure, aggregates of 
amyloid-beta (Aβ) and intraneuronal neurofibrillary tangles.3–5 However, AD is also 
referred to as a degenerative metabolic disease that is associated with physiological 
alterations such as hypercholesterolemia, metabolic syndrome, hypertension and dia-
betes type-2,6 a condition identified as a risk factor for the development of AD.
Pioglitazone (PGZ) (5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]–1,3-
thiazolidine-2,4-diona), an agonist of the peroxisome proliferator-activated recep-
tor (PPARγ), is a thiazolidinedione used for the treatment of type-2 diabetes. The 
PPARγ receptors have various functions including anti-angiogenic, antifibrotic, 
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anti-inflammatory and anti-tumor effects.7–10 PGZ is also 
neuroprotective in models of neurodegenerative disorders,10 
highlighting PPARγ agonists as a promising treatment for 
AD.11 Thus, PGZ has been reported to reduce oxidative 
stress, normalize cerebral blood flow and glucose uptake, 
increase neuronal activity and exert positive effects on 
cerebrovascular functions in an animal model of AD.12 
Furthermore, treatment with PGZ produced a significantly 
lower risk of dementia over the 5-year follow-up period 
in diabetic patients treated with PGZ compared with those 
who were not.13
Drug delivery to the brain is a challenge for the treatment 
of neurological disorders. The blood–brain barrier (BBB) 
is a physical interface between the central nervous system 
(CNS) and peripheral circulation that strictly controls which 
molecules can enter into the brain parenchyma.14 Only lipo-
philic molecules smaller than 400 Da can diffuse through 
the BBB; the passage of lipid insoluble or larger hydrophilic 
molecules is very limited.15,16 Different strategies to increase 
the transport of drugs through the BBB include liposomes, 
solid lipid nanoparticles (NPs), gold NPs and polymeric 
NPs.17–19 These drug-loaded polymeric NPs are a potential 
alternative to improve drug delivery to the brain.
The properties of polymeric NPs include drug encap-
sulation, stability, high loading capacity for many agents 
and controlled drug release kinetics. Moreover, they can be 
easily modified with a variety of surface-attached ligands.20,21 
Different polymers which deliver a variety of molecules 
through the BBB have been studied.22–24 Poly (lactic-co-
glycolic acid) (PLGA) systems have been the subject of 
great scientific interest due to their properties, specifically 
their biocompatibility and biodegradability. PLGA is an 
FDA-approved co-polymer used successfully for delivery 
to different tissues, including the brain.19,25–27
The attachment of specific ligands to the surface of NPs 
makes the delivery of drugs to CNS more targeted and may 
enhance the limited BBB penetration of therapeutic compounds. 
For instance, polyethylene glycol (PEG) can functionalize NPs 
to increase their plasma residence time, preventing their removal 
by mononuclear phagocytes. This allows the NPs to remain lon-
ger in circulation, thus increasing the probability of successful 
organ-targeted delivery and passage across the BBB.28–30
In this study, a formulation of PGZ-PLGA-PEG NPs was 
synthesized and their suitability for the treatment of AD was 
demonstrated. Physicochemical characterization and in vitro 
studies with a human brain microvascular endothelial cell 
line (hCMEC/D3) were carried out. An in vivo study for 
cognitive evaluation after treatment was performed in male 
APP/PS1 mice and wild-type-like (WT) littermates.
Materials and methods
Materials
PGZ was obtained from Capot Chemical (Hangzhou, People’s 
Republic of China) and Diblock copolymer PLGA-PEG 
(Evonik Ind., Resomer® Select 50:50 DLG mPEG 5,000–5 wt% 
PEG), was purchased from Evonik Corporation (Birmingham, 
AL, USA). Rhodamine 6G (Rhod), Tween® 80 (Tw 80), 70 
kDA FITC-dextran and 24-well filter inserts (PET membrane, 
pore 1 µm) were acquired from Sigma-Aldrich (Gillingham, 
UK). The dialysis membrane MWCO 12,000–14,000 Da, 
was obtained from Medicell International Ltd. (London, UK). 
Trypsin-EDTA was purchased from Thermo Fisher (London, 
UK). Alamar Blue (AB) was obtained from Invitrogen Alf-
agene® (Carcavelos, Portugal).
Methods
Optimization and characterization of NPs
PGZ-NPs were obtained by the solvent displacement 
technique.31 The organic phase with PGZ (1 mg/mL) was 
solubilized in dimethyl sulfoxide (DMSO) 5%, to which a 
mixture of PLGA-PEG (9.5 mg/mL) and acetone (5 mL) was 
added. Once completely dissolved, the solution was added 
drop by drop with moderate stirring into 10 mL of an aqueous 
solution of 1.16% Tw 80. The pH was adjusted to 4.5 with 
HCl 0.1 M. Then, the solvents were evaporated and the NP 
dispersion was concentrated into a final volume of 10 mL 
under reduced pressure.
The conditions for NP production were optimized in a fac-
torial design26 (Figure S1). Three independent variables (PGZ, 
PLGA-PEG and Tw 80 concentrations) and four dependent 
variables (average particle size [Z
av
], polydispersity index 
[PI], zeta potential [ZP] and entrapment efficiency [EE] were 
studied. A pH of 4.5 was kept constant for all the assays. 
A total of 16 experiments (eight factorial points, six axial 
points and two replicated center points) were required for the 
estimation of the pure error sum of squares using Statgraphics 
Plus 5.1 software (The Plains, VA, USA). 
The experimental responses were the result of the indi-
vidual influences and interactions of the three independent 
variables. In the surface of response, a low concentration 
of PGZ and PLGA-PEG produced smaller NPs and con-
sequently greater homogeneity of the formulation. The 
formulation with the most appropriate physicochemical 
characteristics was selected for use in this study.
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Transmission electron microscopy (TEM) was used 
to evaluate the morphology of PGZ-NPs. Before negative 
staining, the copper grids were activated with ultraviolet light 
and samples were positioned on the grid surface, diluted with 
water (1:3) and negative stained with a 2% (v/v) uranyl acetate 
solution. After being dried at room temperature, the samples 
were examined by TEM on a Jeol 1010 (Tec-nai Spirit TEM, 
FEI, Jeol, Welwyn Garden City, UK) at 80 kV.
The morphometric parameters (Z
av
 and PI) of PGZ-NPs 
were determined by photon correlation spectroscopy (after 
1:10 dilution with water) with a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK) at 25°C. The surface charge or 
ZP was calculated from electrophoretic mobility. The values 
are the mean ± SD which are calculated for at least three 
different batches.32
The EE of PGZ-NPs was determined indirectly by 
measuring the concentration of the free drug in the disper-
sion medium. The non-entrapped drug was separated by 
a filtration/centrifugation technique (1:10 dilution) using 
Ultracell–100K (Amicon® Ultra; Millipore Corporation, 
Billerica, MA, USA) centrifugal filter devices at 12,000 rpm 
for 15 minutes. The EE was calculated using equation (1):
EE (%)
Total amount of  PGZ Free amount of  PGZ
Total amount 
= −
of  PGZ
100×
 
(1)
Samples were evaluated by HPLC using a validated 
analytical method.33 The mobile phase was: 0.1 M acetonitrile, 
ammonium acetate and glacial acetic acid (75:25:1 v/v), with 
a flow of 0.7 mL/min and a volume of injection of 10 µL. 
The reported values are the mean ± SD (n=6).
Release profile
In vitro PGZ release studies from NPs were performed 
in vertical Franz diffusion cells using membrane dialysis 
with MW 12–14 KDa cutoff under sink conditions27 at 
37.0°C ± 0.5°C with moderate and continuous stirring. The 
PGZ-NPs and free drug at the same concentration (1 mg/mL) 
were dissolved in DMSO and PBS (60:40) and receptor solu-
tion (RS) at pH 7.4 for 23 hours. At specific time intervals, 
a volume of 0.2 mL of the formulations was placed in the 
donor compartment and the receptor compartment was filled 
with the same volume of RS. Amounts of PGZ released were 
measured by HPLC. Values are reported as the mean ± SD 
(n=3). PGZ released at each time point was evaluated and 
data were fitted into different kinetic models34 Akaike’s 
information criterion (AIC) and coefficient of determina-
tion (r2) were determined for each case as an indicator of the 
model’s suitability for each dataset.35
syntheses of rhodamine NPs
To evaluate the cellular uptake of NPs by hCMEC/D3, Rhod 
was incorporated into the NPs. Rhod-NPs were synthesized by 
the same method as PGZ-NPs, but with addition of 100 µg/mL 
Rhod in 500 µL of methanol, mixed with 9.5 mg/mL PLGA-
PEG in 5 mL of acetone (organic phase). After the preparation 
of Rhod-NPs, the EE was determined from the amount of 
the free-Rhod present in the aqueous phase of the formula-
tions, obtained by filtration/centrifugation at 12,000 rpm for 
15 minutes. The amount of Rhod was measured by fluores-
cence spectroscopy (λex 528 nm, λem 547 nm).
cell culture
An immortalized (hCMEC/D3) line36 was cultured in 
endothelial basal medium-2, supplemented with 2.5% fetal 
bovine serum, hydrocortisone, vascular endothelial growth 
factor (VEGF), EGF, insulin-like growth factor I (IGF-I), 
human fibroblast growth factor, ascorbic acid and gentamicin 
sulphate according to the manufacturer’s formulation (Lonza, 
Basel, Switzerland). Cells were grown to confluence on tissue 
culture flasks or inserts coated with collagen Type one from 
calf skin (Sigma, Gillingham, UK) and incubated in 5% CO
2
 
in air at 37°C.
Alamar blue (AB) was used to test for any cytotoxic 
effect of NPs on the hCMEC/D3 cell line. Cells were seeded 
in collagen-coated 96-well plates at 3×104 cells/well and 
were maintained for 24 hours. Then, cells were incubated 
with 100 µL/well of 0.5–10 µg/mL of either PGZ-NPs or 
Rhod-NPs diluted with endothelial culture medium for 
24 hours. After the incubation, hCMEC/D3 cells were treated 
with 10% (v/v) of AB diluted in FBS-free endothelial culture 
medium. Absorbance was measured at 570 nm (reduced AB 
form) and 620 nm (oxidized AB form) between 4–5 hours 
after AB treatment using a FLUOstar OPTIMA microplate 
reader (BMG LABTECH, Ortenberg, Germany). The cell 
viability was calculated by the percentage of AB reduction, 
using the manufacturer’s protocol as described previously.37 
All experiments were performed three times.
cellular uptake of NPs
hCMEC/D3 cells were seeded in 12 well plates (120,000 
cells/well) and grown for 2 days. At confluence, hCMEC/D3 
cells were incubated with 1 µg/mL of Rhod-NPs for 15, 
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30 and 60 minutes, compared with untreated cells and 
analyzed by flow cytometry. The Free-Rhod and Free-Rhod-
NPs (Rhod not encapsulated during NP production) were 
also studied to analyze whether the Rhod could internalize 
without NPs. Fluorescence-activated cell sorting analysis was 
performed by collecting cells with trypsin/EDTA and wash-
ing twice with Hanks balanced salt solution (HBSS) (Sigma 
Aldrich, UK). Washed cells were analyzed on a Becton-
Dickinson (Reading, UK), FACS calibur (FL2 detector set 
at 410V). The experiments were done in triplicate and the 
values are reported as the mean ± SD (n=3) of the median 
fluorescence of 10,000 cells.
hCMEC/D3 monolayers were grown to confluence 
on fibronectin and collagen-coated 8-well Nunc La-Tek 
Chamber slides (Sigma Aldrich, UK). Confluent cells were 
treated with 1 µg/mL of Rhod-NPs for 3 hours at 37°C. Then, 
hCMEC/D3 cells were washed with HBSS and fixed in 4% 
formalin solution for 10 minutes at room temperature. The 
nuclei were counterstained with mounting medium DAPI 
(blue) (Vector Laboratories, Burlingame, CA, USA). Both 
nuclei staining and Rhod-NP-internalization were analyzed 
using confocal laser scanning microscopy (Leica TCS SP5, 
Leica Microsystems, Milton Keynes, UK).
Detection of internalization of NPs by TeM
The internalization of PGZ-NPs and Rhod-NPs in hCMEC/
D3 cells was investigated by TEM. The cells were seeded at 
120,000 cells per 1 cm2 on Transwell® inserts of polyester 
membrane (Costar, Corning, NY, USA). At confluence, the 
NPs (1 µg/mL) were applied to the apical side in endothe-
lial culture medium for 6 hours. Then, both chambers were 
washed three times in HBSS and fixed in 2.5% glutaraldehyde 
for 1 hour at room temperature. The fixative was removed and 
chambers were washed three times with 0.1 M Sörenson’s 
phosphate (PB) and stored in this buffer at 4°C.
In order to process the samples for TEM, all incuba-
tions were applied to both sides of the chamber at room 
temperature. Firstly, the cells were post-fixed in 1% osmium 
tetroxide diluted with 0.1 M PB for 1 hour. Then, the insert 
was washed three times in 0.1 M PB and removed from the 
well. The membrane was cut out of the insert and gradually 
dehydrated in sequence with ethanol: 30% for 5 minutes, 
50% for 5 minutes, 70% for 10 minutes, 100% for 10 minutes 
twice and 100% with a molecular sieve for 10 minutes. Then, 
the membranes were incubated in a mixture of 1:1 ratio of 
100% ethanol and Epon resin overnight. They were embed-
ded in Epon resin and the formed blocks were polymerized 
at 60°C for 48 hours. Resin blocks were micro sectioned at 
80 nm thickness using a Diatome diamond knife. The sections 
were mounted onto pioloform-coated copper grids and 
counter stained in 3.5% uranyl acetate for 35 minutes fol-
lowed by lead citrate for 10 minutes and finally washed three 
times before air-drying. The grids were imaged on TEM JEM 
1010 (Jeol, Japan) at an acceleration voltage of 80 kV using 
a magnification of 25,000–40,000.
Transport and permeability assay
Transfer of NPs across brain endothelium was analyzed 
using permeable cell culture inserts and TEM. Briefly, 
24-well cell-culture inserts (Millipore Millicell Hanging Cell 
Culture Insert, PET membrane; 1 µm) were coated with col-
lagen and fibronectin and seeded with 8×104 cells per insert. 
At confluence, cells were washed with HBSS and cultured 
with endothelial culture medium but without the growth 
factors VEGF, IGF, EGF and maintained for 48 hours. Then, 
cells were treated with 1 µg/mL of PGZ-NPs or Rhod-NPs 
diluted in VEGF, IGF and EGF-free endothelial culture 
medium for 6 hours. The basolateral side-medium was col-
lected and negative stained. NPs (as described above) were 
observed on TEM JEM-1400 operated at an accelerating 
voltage of 80 kV. The experiments were done in triplicate 
and the values are reported as the mean ± SD (n=3).
The effect of the transport of NPs on the hCMEC/D3 
cells was measured by a paracellular permeability assay 
as described previously by Tai et al.38 hCMEC/D3 treated 
with 10 ng/mL of TNFα and IFNγ for 24 hours was used as a 
positive control.39 At the end of these experiments, the api-
cal side-culture medium was removed and 400 µL of assay 
buffer (0.1% BSA in DMEM without phenol red) containing 
2 mg/mL 70 kDa FITC-dextran was added. The fluorescence 
that crossed to the basolateral side was measured every 
10 minutes for 1 hour using a BMG plate reader, and the 
permeability coefficient P
e
 derived.38
In vivo assay with aPP/Ps1 mice
The experiments were carried out in 7 month male APP/PS1 
mice and WT littermates on a C57/Bl6J genetic background. 
The generation of mice, expressing the human mutated 
APPswe and PS1dE9, has been described elsewhere.40 
Animals were maintained under standard animal housing 
conditions in a 12-hour dark-light cycle with free access to 
food and water. Genotypes were confirmed from 1 cm tail 
clips by PCR using conditions recommended by Jackson 
Laboratory. Mice were randomly assigned to treatment 
groups and the experiments were analyzed blind. The study 
was carried out following the guidelines of the European 
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Communities Council Directive 2010/63/EU and with the 
approval of the local ethical committee of the University 
of Barcelona.
Free-PGZ and PGZ-NPs (10 mg/kg) were dissolved in 
5% DMSO and administered orally in a volume of 10 mL/kg 
body weight. Animals were treated once a day, 5 days per 
week, for 4 weeks with the compounds or with the vehicle 
alone. The number of animals included in each group was 
3–4. After a 3-day wash-out, animals were subjected to 
behavioral evaluation.
Memory performance was evaluated with the two-object 
recognition test. On day 1, mice were placed for 9 minutes 
in a Y-maze, in which two identical objects were situated at 
the ends of the arms; the time that the mice spent exploring 
each object was recorded. Then, 24 hours after the training 
session, animals were placed again for 9 minutes in the 
V-maze, with one of the two familiar objects replaced by a 
novel object. The time that the animals spent exploring the 
two objects was recorded and an object recognition index 
(RI) was calculated, as the difference between the time spent 
exploring the novel object (T
N
) and the familiar object (T
F
) 
divided by the total time spent exploring the two objects 
[RI=(T
N
−T
F
)/(T
N
+T
F
)]. At the end of the behavioral testing, 
the animals were killed and their brains rapidly removed from 
the skull, fixed in 4% paraformaldehyde and processed for 
immunohistochemistry.
aβ immunohistochemistry
Fixed tissue samples were embedded in paraffin. Consecu-
tive de-waxed 4 µ coronal sections were incubated with 
98% formic acid (20 M, 3 minutes) and treated with 10 mM 
sodium citrate buffer, pH 6.0, for 20 minutes to enhance anti-
genicity. Endogenous peroxidases were blocked with 10% 
methanol−1% H
2
O
2
 for 15 minutes and then blocked with 
3% normal horse serum in PBS. They were incubated (4°C 
overnight) with primary antibody against Aβ (clone 6F/3D 
1:50, Dako, Denmark) and a peroxidase-conjugated second-
ary antibody, visualized with 7 mM diaminobenzidine in PBS 
(5 minutes). Sections were lightly counterstained with hema-
toxylin. The cortical total Aβ burden was calculated as the 
percentage of the area of amyloid deposition in plaques with 
respect to the total cortical area (0.6 mm2) in nine pictures 
taken from three different sections (−0.1, −1.5 and −2.0 mm 
from bregma) of each animal brain (three pictures per section 
corresponding to cingulate/retrosplenial and motor cortex, 
somatosensory cortex and piriform/entorhinal cortex). The 
selected areas were the main regions of the cerebral cortex in 
which Aβ is deposited in APP/PS1 mice. A researcher who 
did not know the treatments performed the quantifications. 
Aβ quantification was calculated using the Analysis tool of 
Adobe® Photoshop® CS4 (Maidenhead, UK).
statistical analysis
The sample size for experimentation was computed using 
the Power and Precision software (Biostat, Englewood, NJ, 
USA), assuming a power of 95% and no missing data. Data 
were analyzed using GraphPad Prism version 6.0 software. 
Statgraphics Plus 5.1 software was used to analyze the surface 
of response. Student’s t-test or one way ANOVA, followed 
by Tukey’s multiple comparison or Dunnett’s multiple 
comparison test were used to analyze the in vitro assays. 
Statistical analysis for the in vivo assay was performed with 
the SPSS® Statistics v21.0 software (IBM, New York, NY, 
USA). Memory data were analyzed with two-way ANOVA 
(genotype and treatment as between factors), followed by 
Tukey’s post hoc. Aβ area was analyzed with one-way 
ANOVA (treatment as between factors).
Results
PgZ nanocarrier characterization and 
release profile
After a detailed analysis of the parameters affecting NP syn-
thesis (Figure S1), a single formulation of NPs was chosen 
for the biological studies (Figure S2). These PGZ-NPs had 
a mean size of 155.0 ± 1.8 nm, a polydispersity index distri-
bution of 0.1, negative ZP of −13.0 ± 0.5 mV and an EE of 
92.5%. Smaller size facilitates passage through the BBB,16 
and may improve the delivery of drugs. Moreover, low PGZ 
concentrations produced NPs with greater negative ZP that 
could help prevent particle aggregation, thereby increasing 
the stability of the dispersion.41 Importantly, the lower con-
centration of Tw also decreased the toxicity for hCMEC/D3 
cells, besides facilitating interaction with endothelial surface 
molecules and hence, transport across the BBB.42
Different kinetic models of drug release were tested with 
both formulations to select the best fit. The formulations 
showed dissimilar profiles and the best fits were “One phase 
exponential association” for Free-NPs and “hyperbola” for 
PGZ-NPs, with respect to the AIC and coefficient of deter-
mination (r2) values obtained (Figure 1). After 10 hours, the 
free drug achieved 76.2% transfer whereas NPs released 
57.1% of the initially bound drug. In addition, Free-PGZ 
showed a faster release than PGZ entrapped in the particles 
(comparing Y
max
 to B
max
). Free-PGZ had a constant of dis-
solution (K) of 0.46 hour−1 whereas NP-entrapped PGZ had 
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a constant of 1.72 hours. This result indicates that NPs are 
still achieving a sustained release of the drug.
cytotoxicity assay
The in vitro cytotoxicity of PGZ-NPs and Rhod-NPs for 
hCMEC/D3 cells was assessed by determining the cell 
viability using the AB assay (Figure 2). Cells exposed 
to increasing concentrations of PGZ-NPs for 24 hours 
showed decreased cell viability from 5.1 nM (=2 µg/mL) 
(76.56% ± 2.72%). Treatment with Rhod-NPs also produced 
significant toxicity at 5.1 nM and Rhod-NPs were more toxic 
than PGZ-NPs at concentrations from 5.1 nM (P,0.05). 
On the basis of the cytotoxicity assays, the dose of 1 µg/mL 
was selected to investigate the characteristics of both types 
of NPs in vitro.
Transport of NPs by brain endothelium
Rhod was used to track the cellular uptake of NPs by 
hCMEC/D3 cells. NPs prepared using Rhod showed high EE 
(around 99%) and remained associated with the cells for 
extended periods of time. The cellular uptake of Rhod-NPs 
into hCMEC/D3 was measured at 15, 30 and 60 minutes by 
FACS. The values of fluorescence of Rhod-NPs increased in 
a dose and time-dependent manner (P,0.05) when compared 
to untreated cells (Figure 3). The uptake was time-dependent 
with significant uptake of NPs within the first 15 minutes of 
exposure. The fluorescence in Rhod-NPs treated hCMEC/D3 
cells was .50x higher than cells exposed to Free-Rhod 
(Figure 3C).
routes of transcytosis
To determine the subcellular localization of the NPs, 
hCMEC/D3 cells were treated with Rhod-NPs and examined 
by confocal microscopy (Figure 4). Red punctate fluores-
cence was observed in all cells; the size corresponded to 
individual NPs localized primarily in the cell body, close 
to the nucleus. These observations confirm the results 
obtained by FACS which demonstrated that all cells take up 
the Rhod-NPs (Figure 3A) and that the fluorescence signal 
was much higher when using Rhod-NPs in comparison to 
Free-Rhod. It has been proposed that internalization of NPs 
of this size occurs predominantly by adsorption to the cell 
surface followed by vesicular endocytosis. The results are 
consistent with NP-uptake into either caveolae or clathrin-
coated vesicles (CCVs).
Confocal microscopy has insufficient resolution to 
determine exactly where the NPs are localized within the 
cells. To obtain a better understanding of the mechanism of 
NPs uptake, the cells were examined by TEM. The images 
show individual PGZ-NPs and Rhod-NP (100–150 nm) in 
the cytoplasm (Figure 5); the size corresponds to their initial 
physical characterization (Figure S2). No NPs were seen 
in intercellular junctions. This implies that the NPs have 
been taken up individually by endothelial cells and have not 
aggregated inside the cells. It is not possible to see a distinct 
vesicle membrane or electron-dense coat proteins around 
Figure 1 Release profile of PGZ from PGZ-NPs and Free-PGZ.
Abbreviations: PgZ, pioglitazone; NP, nanoparticles; aIc, akaike’s information 
criterion.
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the NPs. However, it should be noted that both caveolae and 
CCVs are normally smaller (50–100 nm) than these NPs; 
hence a caveolus or CCV would contain just one NP and 
the closely apposed vesicular membrane would be difficult 
to visualize by TEM. Notably, NPs were not seen in larger 
pinocytotic vesicles or intercellular junctions. Nor was there 
any evidence of disturbance of the plasma membrane. These 
observations exclude paracellular movement as the route of 
movement and direct trans-membrane transfer to the cytosol 
is also unlikely. Hence, the most likely route of uptake across 
the endothelium is via endocytosis from the apical surface 
into a single CCV or caveolus. This is in accordance with 
the observed clustering of the NPs in the perinuclear region 
seen by confocal fluorescence microscopy, which is a char-
acteristic of caveolae.
Transport and permeability assays
To determine whether NPs are released from the baso-
lateral side of the endothelium, hCMEC/D3 cells were 
grown in confluent monolayers on filters in tissue-culture 
inserts. PGZ-NPs and Rhod-NPs were applied to the apical 
surface and the medium harvested from the basolateral 
side. After 6 hours, NPs had crossed the endothelial mono-
layer (Figures 6A and S3). The NPs were similar in size 
(100–200 nm) to those initially applied, suggesting they had 
crossed the endothelium intact.
The integrity of the cell monolayer after exposure to 
both types of NPs was assessed using a paracellular tracer, 
FITC-dextran (MW 70 kDa). Changes in the permeability 
coefficient were calculated and the data show that treatment 
of hCMEC/D3 cells with PGZ-NPs and Rhod-NPs for 
6 hours does not increase the paracellular permeability of 
the endothelial monolayer (Figure 6B). This demonstrates 
that the NPs had not altered paracellular permeability of the 
endothelial monolayer, and further confirms that the NPs seen 
in Figure 6A had crossed the endothelium by transcytosis.
effect of treatment on memory and 
neuropathology in aPP/Ps1 mice
In order to test the in vivo effect of the PGZ-NPs, a com-
parison was made with Free-PGZ in APP/PS1 mice. Oral 
administration was chosen as this reflects the route of PGZ 
administration in humans. Previous work has shown that 
exposure of these NPs to acid (0.1 M HCl) for 15 minutes 
(reflecting gastric conditions) followed by neutralization 
does not affect their size, ZP, PI or EE. Daily administra-
tion of Free-PGZ and PGZ-NPs (10 mg/kg) for 4 weeks 
reduced the memory impairment observed in vehicle-treated 
APP/PS1 mice, as revealed by the two-object recognition 
test (Figure 7A). Two-way ANOVA revealed a significant 
genotype [F
(1, 16)
=5.413, P,0.05] and treatment effect 
[F
(2, 16)
=12.717, P,0.001] and interaction between the two 
factors [F
(2, 16)
=3.551, P=0.053]. Subsequent Tukey’s post hoc 
tests revealed that APP/PS1 mice treated with vehicle exhib-
ited a memory impairment when compared to correspond-
ing WT littermates (P,0.01) and that Free-PGZ (P,0.05) 
and PGZ-NPs (P,0.01) increased the recognition index in 
APP/PS1 mice when compared to vehicle. No significant 
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Abbreviations: PgZ-NPs, PgZ-loaded nanoparticles; rhod-NPs, rhod-nanoparticles; hcMec/D3, human brain endothelial cell line; TeM, transmission electron microscopy.
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difference in the total exploration time during the memory 
acquisition session or the memory test was observed between 
groups, discounting any possible impact of the treatments on 
the anxiety levels or the activity of the mice.
Chronic treatment with Free-PGZ or PGZ-NPs did not 
significantly modify [F
(2, 8)
=2.993, P=0.04] the total Aβ 
burden in the cortex with respect to vehicle-treated mice 
(Figure 7B and C). The vehicle employed in this study did 
not induce any modification in Aβ burden when compared 
to untreated mice (data not shown). Notably, the level of Aβ 
deposition in mice treated with PGZ-NPs was half of that in 
mice treated with Free-PGZ (Figure 7); however there was 
considerable variation between individual animals. These 
results demonstrate that a PPARγ agonist improves memory 
in APP/PS1 mice and suggest that encapsulation of PGZ in 
NPs can reduce the Aβ burden.
Discussion
In this study, we have demonstrated that PGZ-NPs devel-
oped by a displacement technique are appropriate for the 
treatment of a model of AD. The release profile from NPs 
was slower than Free-PGZ. Moreover, the NPs were not 
cytotoxic for human brain endothelium (hCMEC/D3) at the 
doses used and produced no alteration in permeability of the 
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Figure 6 (A) Images of PgZ-NPs and rhod-NPs by TeM after 6 hours in the basolateral compartment. (B) Permeability of hcMec/D3, following exposure to 1 µg/ml of 
NPs for 6 hours. TNFα+ IFNγ (10 ng/ml, for 24 hours) was used as a positive control, increasing endothelial permeability.
Notes: each value is the mean of three independent experiments. ns=nonsignificant, *P,0.05 by one-way aNOVa and Dunnett’s multiple comparison test (n=3).
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endothelial monolayer. These results are in accordance with 
a previous study using mouse Bend-3 cells, which indicated 
that PLGA-PEG NPs did not damage endothelial cells.19
Theoretically, endocytosis of NPs can occur by pas-
sive transfer across the cell membrane into the cytoplasm 
or by active endocytosis into vesicles, including CCVs 
and caveolae. NP size affects the principal entry route; 
the smallest NPs (,10 nm) can directly cross the plasma 
membrane whereas endocytosis is the principal entry route 
for larger NPs.43
The route of endocytosis depends greatly on how the 
NPs interact with different domains of the plasma mem-
brane, which is affected by size, coating, surfactant and 
surface charge as well as any specific targeting molecule 
on the NPs. These factors may also affect the ability of the 
NPs to cross the BBB in vivo.44 The subcellular localization 
of NPs in this study, determined by confocal and electron 
microscopy, indicated that they cross the endothelium intact 
by vesicular transcytosis.
Most endothelial cells have large numbers of caveolae 
which mediate transport of nutrients to the tissue.45 However, 
brain endothelium in vivo has relatively few caveolae com-
pared with endothelium in other tissues and consequently 
there is less internalization by this route. However, PEG 
on the surface of NPs can improve their internalization by 
brain endothelium46 and it has been suggested that PEGylated 
PLGA NPs could enter these cells in CCVs47 as an alternative 
to caveolar transcytosis. CCVs have previously been shown 
to play a key role in the transportation of PEGylated NPs in 
which energy-dependent endocytosis is involved.48 Moreover, 
particles up to 200 nm in diameter can be efficiently taken up 
into CCVs.49 The 50-fold higher rate of uptake of Rhod-NPs 
compared with free rhodamine also implies that the NPs are 
taken up by a different mechanism than the free tracer.
These observations indicate that the PGZ-NPs enter and 
can potentially cross brain endothelium directly. Transcytosis 
of NPs within vesicles shields any cargo molecule such as 
PGZ or rhodamine from ABC-transporters (eg, pgp/ABCB1), 
located in the apical plasma membrane, which act on sub-
strates in the cytoplasm and/or the membrane. Even if the NPs 
enter the cytoplasm, the delayed release of cargo means that 
less drug can be removed by multi-drug transporters.
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Figure 7 In vivo evaluation of PgZ-NPs.
Notes: (A) Memory performance of treated animals in the two-object recognition test. aPP/Ps1 animals treated with vehicle showed cognitive impairment when compared 
with wild-type littermates. In contrast, Free-PgZ and PgZ-NPs treatment reduced the memory impairment in aPP/Ps1 mice. (B) cortical aβ burden is not significantly 
modified in treated APP/PS1 mice, in spite of the tendency to decreased deposition in NP-PGZ-treated animals. (C) representative images of aβ immunoreactivity in cortical 
sections of aPP/Ps1 mice chronically treated with Free-PgZ, PgZ-NPs or vehicle. scale bar=200 µm. Data are expressed as the mean ± seM. **P,0.01 compared to WT 
animals. $P,0.05, $$P,0.01 compared to vehicle group.
Abbreviations: PgZ-NPs, PgZ-loaded nanoparticles; PgZ, pioglitazone; WT, wild-type; Veh, vehicle. 
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The experiments in vivo demonstrated the potential for 
PGZ, and particularly PGZ-NPs, to reduce memory deficit 
and neuropathology in APP/PS1 mice. These results are in 
accordance with Searcy et al50 who demonstrated that Free-
PGZ improved reversal learning in a triple transgenic mouse 
model of AD mice. Moreover, other studies showed that 
APP/PS1 mice treated for nine days with PGZ reversed non-
cognitive behavioral deficits and restored distance and speed 
traveled in an open field51 and, improved partially, the cogni-
tive impairments in the Morris water maze test.52 A number 
of other studies have reported neuroprotective properties 
of PGZ.9,10,50,52,53 Moreover, the Phase III clinical trial also 
demonstrated a role for PGZ in slowing cognitive decline in 
people with mild cognitive impairment due to AD.54
In this study, the overall reduction in Aβ burden in PGZ-
NPs treated mice was striking although individual results 
were variable. Previous work has also produced divergent 
results. In one other study, the amyloidogenic APP process-
ing and Aβ production were not affected by treatment with 
pioglitazone.51 In contrast, an acute 2-week treatment with 
combined leptin and PGZ resulted in a reduction of spa-
tial memory deficits (Y maze) and brain β-amyloid levels 
(soluble β-amyloid and amyloid plaque burden) relative to 
vehicle-treated animals.55
Conclusion
The overall conclusion from our study is that PGZ-NPs 
reduce memory impairment and neuropathology in APP/
PS1 mice. However, it is not certain whether the release 
of PGZ from NPs in vivo occurs inside the CNS or outside 
the CNS. The results indicate that any difference between 
the effect of Free-PGZ and PGZ-NPs is most likely due to 
either the slower release profile from PGZ-NPs (Figure 1) or 
the improved rate of transcytosis across brain endothelium 
(Figures 3–6) with the potential for evading the action of 
multi-drug transporters at the blood–brain barrier.
The data all confirm that NPs cross endothelial cells 
in vitro without affecting cellular integrity. Moreover, PGZ 
encapsulated into polymeric NPs (PLGA-PEG) improved 
the cognitive deficit in APP/PS1 male mice in a similar way 
to Free-PGZ, and showed a clear tendency to reduce beta 
amyloid deposition in the cerebral cortex, suggesting that 
PGZ-NPs are a new alternative to treat AD, both improv-
ing drug delivery into the brain and providing for a more 
sustained drug release.
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Figure S1 Design of experiments. response surfaces of PgZ-NPs at Tw 80 1.16%, with different concentrations of PgZ and Plga-Peg: (A) Zav, (B) PI, (C) ZP and (D) ee.
Abbreviations: PgZ-NPs, PgZ-loaded nanoparticles; PgZ, pioglitazone; Plga-Peg, poly (lactic-co-glycolic acid) polyethylene glycol; Zav, average particle size; PI, polydisper-
sity index; ZP, zeta potential; EE, entrapment efficiency.
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Figure S2 (A) Image of PgZ-NPs by TeM and (B) size of PgZ-NPs by dynamic 
light scattering.
Abbreviations: PgZ-NPs, PgZ-loaded nanoparticles; TeM, transmission electron 
microscopy.
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Figure S3 Transport in vitro assay in hcMec/D3. 
Note: PGZ-NPs on the basolateral surface (filter side) of the endothelium after 
6 hours.
Abbreviations: PgZ-NPs, PgZ-loaded nanoparticles; hcMec/D3, human brain 
endothelial cell line.
